Crossmark

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Crossref DOI link: https://doi.org/10.1186/s12885-021-08588-9

Published Online: 2021-09-06

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ye, Wu

Wu, Xia

Liu, Xiaoyan

Zheng, Xue

Deng, Jili

Gong, Yuping https://orcid.org/0000-0002-2437-9348
Funding

Funding for this research was provided by:

Department of Science and Technology of Sichuan Province (NO.2019YFS0026)
License Information

Text and Data Mining valid from 2021-09-06

Version of Record valid from 2021-09-06
More Information

Article History

Received: 10 November 2020

Accepted: 5 July 2021

First Online: 6 September 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below